Key Points
- Director Jack Schuler bought 20,000 shares of Biodesix at an average price of $11.80 on Jan. 26, a $236,000 purchase that raised his direct stake to 1,563,210 shares (a 1.30% increase), as disclosed in an SEC filing.
- Biodesix shares opened at $11.08, trade above their 50- and 200-day moving averages (~$7.75), have a 12-month range of $3.44–$21.60 and a market cap of $88.15 million; the company reported Q3 EPS of ($1.16) beating estimates but still shows negative margins and ROE.
- Analysts are mixed but leaning positive with an average rating of “Moderate Buy” and a $32.50 average target, while institutional investors own about 20.96% of the stock and several funds have recently adjusted positions.
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler bought 20,000 shares of the business's stock in a transaction on Monday, January 26th. The shares were acquired at an average price of $11.80 per share, with a total value of $236,000.00. Following the completion of the purchase, the director directly owned 1,563,210 shares of the company's stock, valued at approximately $18,445,878. The trade was a 1.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Biodesix Stock Performance
Shares of BDSX stock opened at $11.08 on Wednesday. The business's 50-day moving average price is $7.75 and its 200-day moving average price is $7.73. Biodesix, Inc. has a 12 month low of $3.44 and a 12 month high of $21.60. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The firm has a market capitalization of $88.15 million, a price-to-earnings ratio of -1.99 and a beta of 0.60.
Biodesix (NASDAQ:BDSX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.60) by $0.44. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. The firm had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. Equities research analysts forecast that Biodesix, Inc. will post -0.35 EPS for the current year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on BDSX shares. Weiss Ratings restated a "sell (e+)" rating on shares of Biodesix in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of Biodesix from a "sell" rating to a "hold" rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Biodesix presently has an average rating of "Moderate Buy" and an average target price of $32.50.
View Our Latest Stock Analysis on Biodesix
Institutional Investors Weigh In On Biodesix
Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in Biodesix in the third quarter valued at approximately $113,000. Oracle Investment Management Inc. acquired a new position in shares of Biodesix during the 3rd quarter valued at $113,000. XTX Topco Ltd lifted its position in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares during the period. Finally, Aberdeen Group plc bought a new position in Biodesix during the fourth quarter worth $1,784,000. 20.96% of the stock is currently owned by institutional investors.
Biodesix Company Profile
(
Get Free Report)
Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.
The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
